Author： Frey Simon Linder Roland Juckel Georg Stargardt Tom
Publisher： Springer Publishing Company
ISSN： 1618-7598
Source： The European Journal of Health Economics, Vol.15, Iss.2, 2014-03, pp. : 133-142
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise
By Heeg B. M. S. Antunes J. Figueira M. L. Jara J. M. Marques Teixeira J. Palha A. P. Vaz Serra A. Buskens E. Caleo S. Gouveia-Pinto C. Van Hout B. A.
Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. :
Access to resources
Recommend
By Einarson Thomas R. Pudas Hanna Zilbershtein Roman Jensen Rasmus Vicente Colin Piwko Charles Hemels Michiel E. H.
Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. :
Injectable risperidone shows effectiveness in first‐episode schizophrenia
THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol. 1068-5308, Iss. 10, 2015-10 ,pp. :
By Peuskens J. Olivares J.M. Pecenak J. Tuma I. bij de Weg H. Eriksson L. Resseler S. Akhras K. Jacobs A.
Current Medical Research and Opinion, Vol. 26, Iss. 3, 2010-03 ,pp. :